MarketLens
Sign Up

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

4 months ago
SHARE THIS ON:

What is Latus Bio's "Gene Therapy 2.0" and Why Does it Matter

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 months ago

Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 Gangliosidoses

Andelyn Biosciences will use its Curator® platform to develop and manufacture AAV9-GM2 gene therapy for Queen's University, targeting GM2 gangliosidoses. The collaboration advances a potential treatme...
Stock News1 months ago

Prime Medicine: Soon In The Clinic

Prime Medicine's $548M valuation may understate its gene-editing pipeline across five indications, after IND/CTA clearances, RMAT designation, and patent wins. Shares fell 54% from 52-week highs despi...
Stock News1 months ago

Taysha Gene Therapies Q2 Earnings Call Highlights

Taysha Gene Therapies completed dosing in its REVEAL pivotal and ASPIRE trials for TSHA-102, its Rett syndrome gene therapy candidate, positioning the company for a potential biologics license applica...

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

BABA 13-DAY DEADLINE ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 5, 2026 Lead Plaintiff Deadline

Stock News2 hours ago

Nasdaq Scores Record As Oil Eases; Apple Tests Buy Point

Stock News2 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alibaba Group Holding Limited of Class Action Lawsuit and Upcoming Deadlines – BABA

Stock News2 hours ago

Meta Was the Worst AI Lab

Stock News3 hours ago

Why Apple could soon join Nvidia in the exclusive $5 trillion club